GLAND / FY26 summary

The year in one view.

Gland Pharma · annual summary assembled from the available FY26 source records.

Research layer active

Revenue across quarters

17,716.3

₹ Cr where applicable

PAT across quarters

2,497.5

₹ Cr where applicable

Source quarters

12

₹ Cr where applicable

EBITDA (₹ Cr)PositiveWatchNegative
12 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY24: 298.2 · Watch source sentiment · 2023-08-09Q1 FY24Q2 FY24: 320.5 · Watch source sentiment · 2023-11-09Q2 FY24Q3 FY24: 355.7 · Watch source sentiment · 2024-02-12Q3 FY24Q4 FY24: 358.7 · Positive source sentiment · 2024-05-14Q4 FY24Q1 FY25: 266.4 · Watch source sentiment · 2024-08-14Q1 FY25Q2 FY25: 296.1 · Watch source sentiment · 2024-10-30Q2 FY25Q3 FY25: 360 · Watch source sentiment · 2025-01-23Q3 FY25Q4 FY25: 347.5 · Watch source sentiment · 2025-05-15Q4 FY25Q1 FY26: 367.8 · Positive source sentiment · 2025-08-01Q1 FY26Q2 FY26: 313.9 · Positive source sentiment · 2025-11-06Q2 FY26Q3 FY26: 449 · Positive source sentiment · 2026-01-15Q3 FY26Q4 FY26: 524.4 · Positive source sentiment · 2026-05-15Q4 FY26524.4266.4
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.